Bisphenol A in Thermal Paper Receipts: An Opportunity for Evidence-Based Prevention by Schwartz, Andrea W. & Landrigan, Philip J.
Correspondence
A 14  v o l u m e 120 | number 1 | January 2012  •  Environmental Health Perspectives
exposure scenarios. In comparing our rough 
“equiva  lent” estimates obtained based on life‑
time exposure to concentrations currently 
being used for in vitro testing, we indeed 
intended to highlight that such concentra‑
tions represent a high end bounding limit, 
as Oberdörster has emphasized. Equivalent 
in vitro concentrations based on a 24‑hr sce‑
nario are intended to represent more realistic 
short‑term exposures.
We agree with Oberdörster that our article 
(Gangwal et al. 2011) should not be viewed as 
justification for using very high NM in vitro 
testing concentrations. Rather, we demon‑
strate the importance of understanding in vitro 
concentrations in the context of the potential 
for human NM exposure to improve study 
design and facilitate interpretation of testing 
results. For NMs currently being tested in 
the U.S. Environmental Protection Agency’s 
(EPA) ToxCast project (Dix et al. 2007), we 
are in fact evaluating multiple concentrations 
based on consideration of potential exposure 
and generally have set NM testing concentra‑
tions to range from below the 24‑hr inhala‑
tion exposure equivalent to the full working 
lifetime equivalent.
As we note in our article (Gangwal 
et al. 2011) and as Oberdörster has further 
emphasized, there are significant uncertain‑
ties associated with our estimates of expo‑
sure and associated dosing concentrations. 
These include uncertainties associated with 
screening‑level tools available for modeling 
deposition of engineered nano  materials and 
with our understanding of charac  teris  tics and 
properties of materials found in the human 
environment. In the interest of mining avail‑
able tools to inform design of toxicity tests 
for immediate use, we did opt to make sig‑
nificant simplifying assumptions related to 
particle charac  teristics and to apply a version 
of the MPPD model adapted by the develop‑
ers for application to nano  fibers/nano  tubes 
(National Institute for Occupational Safety 
and Health 2008). The modeled alveolar 
mass retained for CNTs based on more realis‑
tic, short 24‑hr inhalation exposure duration 
is available online (U.S. EPA 2011).
One point that Oberdörster missed in 
our article (Gangwal et al. 2011) is that we 
calculated alveolar lung surface concentra‑
tion using the same low estimate of human 
alveolar surface area for both the full working 
lifetime and the 24‑hr exposure duration, and 
thus calculations for both exposure scenarios 
may be lower by approximately one order of 
magnitude. 
We are pleased that our framework for 
using available exposure information to 
inform selection of in vitro toxicity testing 
concentrations is generating important dis‑
cussion. We believe the issues and limitations 
raised in our article and by Oberdörster are 
important and demonstrate a critical need 
for continuing research to understand the 
potential for human exposure to engineered 
nano  materials and to design environ  mentally 
relevant toxicity testing schemes. 
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The recent report by Taylor et al. (2011) on 
the pharmaco  kinetics of bisphenol A (BPA) 
emphasizes the similarities between humans, 
monkeys, and mice in the metabolism of this 
ubiquitous and potentially toxic synthetic 
chemical. The authors suggested that human 
exposure to BPA may be “much higher than 
previously assumed.” They observed that 
a potentially important non  food source of 
exposure to BPA may be the thermal paper 
used in cash register receipts. 
BPA is found in receipt paper (Mendum 
et al. 2010) and appears to transfer read‑
ily from receipts to skin (Biedermann et al. 
2010) and to be absorbed trans  dermally 
(Zalko et al. 2011). Retail workers, who likely 
have more frequent exposure to cash receipts 
containing BPA than other Americans, have 
been found to have elevated levels of urinary 
BPA (Lunder et al. 2010). BPA has been 
shown to be capable of crossing the placenta 
(Balakrishnan et al. 2010) and to be toxic dur‑
ing early mammalian develop  ment (vom Saal 
and Hughes 2005). This toxicity is rele  vant to 
humans, given the similarities in BPA metab‑
olism observed across species by Taylor et al. 
(2011). Prenatal exposure of human infants 
to BPA has been associated with behavioral 
anomalies (Braun et al. 2009).
There is a sense of déjà vu about this story: 
In the 1970s polychlorinated biphenyls (PCBs) 
were widely used in carbonless copy paper 
(Erickson and Kaley 2011). PCBs were shown 
to be absorbed through the skin (Carpenter 
2006), and prenatal exposures to PCBs were 
subsequently shown to cause irreversible brain 
injury to developing fetuses, which resulted in 
permanent loss of IQ (intelli  gence quotient) 
and alterations in behavior (Jacobson and 
Jacobson 1997). This exposure ended when 
the manufacture of PCBs was banned in the 
United States in 1976. 
The research of Taylor et al. (2011) con‑
tributes to our understanding of the poten‑
tial harms to the developing fetus from 
BPA. These findings under  score the need 
to develop a new U.S. chemical policy that 
would require toxicological testing of widely 
used chemi  cals already on the market and 
pre  market safety testing of all proposed new 
chemicals (Landrigan and Goldman 2011). 
The time to presume that chemicals are safe 
until they are proven beyond all doubt to 
cause injury to America’s children is past. 
While research into the effects of exposure 
to BPA continues, we have an opportunity 
to act today on the basis of the available evi‑
dence to remove BPA from thermal paper, 
as we strive to protect the health and future 
intelligence of America’s children.
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We agree with Schwartz and Landrigan that 
there is a need for change in the regulatory 
system for chemicals used in products in the 
United States. Bisphenol A (BPA) is one of 
thousands of chemicals of concern, but it 
provides a striking example of what happens 
when there is no requirement for premarket 
testing. Full estrogenic activity was demon‑
strated for BPA when it was tested for use 
as a pharmaceutical drug in 1936, which 
should have precluded its use in the wide 
range of products that results in continuous 
exposure (Stahlhut et al. 2009). The find‑
ings we reported in our article (Taylor et al. 
2011) show that clearance of BPA in mice, 
monkeys, and humans does not differ, and 
years of research has demonstrated that mice 
and rats are valid models for predicting the 
long‑term adverse consequences of develop‑
mental exposure to estrogenic chemicals. A 
vast and rapidly growing number of stud‑
ies with experi  mental animals (Richter et al. 
2007) and humans (Braun and Hauser 2011) 
report adverse effects later in life as a result of 
exposure to BPA during development.
In the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) 
study, the Centers for Disease Control and 
Prevention estimated that 93% of people in 
the United States are exposed to BPA, with 
higher exposures in children than adults. 
The potential exposure of fetuses and infants 
to BPA is especially concerning because 
BPA is not metabolized effectively dur‑
ing these highly sensitive stages of human 
development. Our data (Taylor et al. 2011) 
indicate that to reach the median serum 
levels of unconjugated (bioactive) BPA 
reported in multiple biomonitoring studies 
(Vandenberg et al. 2010), exposure must 
be far higher than predicted by the Food 
and Drug Administration (FDA) based on 
its risk assessment of BPA (FDA 2008); 
these govern  ment estimates (FDA 2008) are 
based on kinetics after acute oral exposure 
and the assumption that food and beverage 
packaging is the only source of BPA expo‑
sure. However, data from the 2003–2004 
NHANES (Stahlhut et al. 2009) confirmed 
that BPA exposure is likely to be from mul‑
tiple sources—including thermal receipt 
paper—and there is evidence that in adults 
different forms of exposure do not have the 
same meta  bolic profile (Sieli et al. 2011).
We find it disturbing that government 
agencies continue to argue that the public 
should not be concerned about BPA because 
daily exposures are below “safe” levels. This 
conclusion is based on flawed studies using 
outdated approaches. We agree with Schwartz 
and Landrigan that we have to stop repeat‑
ing the same mistakes made previously with 
chemicals such as lead, for which, after 
decades of repeatedly lowering “safe” exposure 
estimates, the current predicted “safe” level is 
still above levels now known to cause adverse 
effects. For endocrine‑disrupting chemicals 
there are no threshold doses below which 
exposures are safe (Sheehan 2006), a reality 
that regulators are unwilling to acknowledge.
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Artificial Food Color Additives and 
Child Behavior 
http://dx.doi.org/10.1289/ehp.1104409
In his commentary, Weiss (2012) dis‑
cusses results of the recent Food and Drug 
Administration (FDA) evaluation of the pos‑
sible association between artificial food color 
additives (AFCs) and adverse behaviors in 
children, including those related to hyper‑
activity. The stated aim of the commentary 
is “to examine the basis of the FDA’s posi‑
tion, the elements of the review that led to its 
decision and that of the committee, and the 
reasons why this is an environmental issue.” 
In the commentary, however, a) the FDA’s 
petition review and safety assessment pro‑
cesses are misconstrued; b) the range of nor‑
mal behaviors and the levels at which these 
behaviors can be considered adverse are not 
distinguished, and comparisons that cloud 
the distinction are unsupported; c) exam‑
ples from individual studies are used out of 
context or irrespective of the conclusions 
expressed by the authors; d) specific results 
are cited from studies the FDA concluded 
were fundamentally flawed; and e) compre‑
hensive reviews by other scientific panels are 
not mentioned. As a result, the viewpoint 
presented does not properly characterize the 
public health issue, the FDA’s evaluation 
and conclusions, or the processes involved, 
including the FDA’s proposed actions. This 
letter addresses as many general errors, omis‑
sions, and apparent flaws in the commentary 
as space permits. 
In 2008, the Center for Science in the 
Public Interest (CSPI) petitioned the FDA 
to ban eight AFCs based primarily on results 
from clinical challenge studies on behavioral 
effects of these chemicals in children with a 
history of hyper  activity disorders or related 
behavioral problems (CSPI 2008). The peti‑
tion also cited studies that tested potential 